Literature DB >> 12509458

The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Kristie L Durst1, Bart Lutterbach, Tanawan Kummalue, Alan D Friedman, Scott W Hiebert.   

Abstract

Inversion(16) is one of the most frequent chromosomal translocations found in acute myeloid leukemia (AML), occurring in over 8% of AML cases. This translocation results in a protein product that fuses the first 165 amino acids of core binding factor beta to the coiled-coil region of a smooth muscle myosin heavy chain (CBFbeta/SMMHC). CBFbeta interacts with AML1 to form a heterodimer that binds DNA; this interaction increases the affinity of AML1 for DNA. The CBFbeta/SMMHC fusion protein cooperates with AML1 to repress the transcription of AML1-regulated genes. We show that CBFbeta/SMMHC contains a repression domain in the C-terminal 163 amino acids of the SMMHC region that is required for inv(16)-mediated transcriptional repression. This minimal repression domain is sufficient for the association of CBFbeta/SMMHC with the mSin3A corepressor. In addition, the inv(16) fusion protein specifically associates with histone deacetylase 8 (HDAC8). inv(16)-mediated repression is sensitive to HDAC inhibitors. We propose a model whereby the inv(16) fusion protein associates with AML1 to convert AML1 into a constitutive transcriptional repressor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509458      PMCID: PMC151524          DOI: 10.1128/MCB.23.2.607-619.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  Molecular insights into PEBP2/CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta.

Authors:  M Goger; V Gupta; W Y Kim; K Shigesada; Y Ito; M H Werner
Journal:  Nat Struct Biol       Date:  1999-07

2.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia.

Authors:  L H Castilla; L Garrett; N Adya; D Orlic; A Dutra; S Anderson; J Owens; M Eckhaus; D Bodine; P P Liu
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

Review 3.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

Authors:  A Melnick; J D Licht
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

4.  Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.

Authors:  X Zhou; V M Richon; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

5.  A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia.

Authors:  B Lutterbach; J J Westendorf; B Linggi; S Isaac; E Seto; S W Hiebert
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

6.  Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor.

Authors:  T Nomura; M M Khan; S C Kaul; H D Dong; R Wadhwa; C Colmenares; I Kohno; S Ishii
Journal:  Genes Dev       Date:  1999-02-15       Impact factor: 11.361

7.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Authors:  J Wang; T Hoshino; R L Redner; S Kajigaya; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.

Authors:  N Adya; T Stacy; N A Speck; P P Liu
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

9.  Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

Authors:  V Gelmetti; J Zhang; M Fanelli; S Minucci; P G Pelicci; M A Lazar
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.

Authors:  B Lutterbach; J J Westendorf; B Linggi; A Patten; M Moniwa; J R Davie; K D Huynh; V J Bardwell; R M Lavinsky; M G Rosenfeld; C Glass; E Seto; S W Hiebert
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  51 in total

Review 1.  Histone Deacetylases in Bone Development and Skeletal Disorders.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Andre J van Wijnen; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

2.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

3.  Inhibition of Interleukin 1β (IL-1β) Expression by Anthrax Lethal Toxin (LeTx) Is Reversed by Histone Deacetylase 8 (HDAC8) Inhibition in Murine Macrophages.

Authors:  Soon-Duck Ha; Chantelle Reid; Shahab Meshkibaf; Sung Ouk Kim
Journal:  J Biol Chem       Date:  2016-02-24       Impact factor: 5.157

4.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

Review 5.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

6.  Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.

Authors:  Heehyoung Lee; Nilanjan Sengupta; Alejandro Villagra; Natalie Rezai-Zadeh; Edward Seto
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

7.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

8.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.

Authors:  R Katherine Hyde; Yasuhiko Kamikubo; Stacie Anderson; Martha Kirby; Lemlem Alemu; Ling Zhao; P Paul Liu
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

9.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

10.  The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis.

Authors:  Yasuhiko Kamikubo; R Katherine Hyde; Ling Zhao; Lemlem Alemu; Cecilia Rivas; Lisa J Garrett; P Paul Liu
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.